OraSure Technologies (OSUR) opened 2026 with Q1 revenue of US$27.9 million and a basic EPS loss of US$0.32, alongside a trailing twelve month revenue base of US$113.0 million and a basic EPS loss of US$1.04. Over recent quarters the company has seen revenue move from US$29.9 million in Q1 2025 and US$37.4 million in Q4 2024 to the latest US$27.9 million print. Quarterly basic EPS losses shifted from US$0.21 and US$0.14 in those periods to US$0.32, so investors are likely to focus on how quickly margins can stabilize from here.

See our full analysis for OraSure Technologies.

With the headline numbers on the table, the next step is to see how this earnings profile lines up with the main narratives around OraSure Technologies, and where the recent margin trends support or challenge those views.

Losses Deepen To US$22.4 Million On Similar Revenue

• Q1 2026 net loss was US$22.4 million on US$27.9 million of revenue, compared with US$19.3 million on US$26.8 million in Q4 2025, so the company is generating similar sales each quarter while losses have been larger than US$13 million in every quarter since Q2 2025.
• Bulls point to new at home diagnostics and broader infectious disease testing as future growth drivers. However, the trailing twelve month loss of US$75.1 million on US$113.0 million of revenue highlights how far current margins are from the bullish narrative that expects improved efficiency and higher earnings over time.
  • Supporters highlight planned benefits from automation and manufacturing changes, but quarterly net losses widened from US$10.8 million in Q4 2024 to US$22.4 million in Q1 2026, which contrasts with the idea of near term operating leverage.
  • The bullish case leans on new product launches and partnerships, while the reported 5.5% annualized revenue growth over the last 12 months shows only modest top line expansion so far.

Bulls arguing that new product launches and efficiency projects could eventually change this picture may want to see how those storylines line up against the full range of community views in more detail before leaning too heavily on them 🐂 OraSure Technologies Bull Case

Five Year Loss Growth Versus Modest 5.5% Revenue Trend

• Over the past five years, losses have grown at about 18.9% per year while revenue growth over the last 12 months is reported at 5.5% a year and sits below the 11.4% US market growth rate cited in the data.
• Bears argue that reliance on public health funding and a limited product set makes this slower 5.5% revenue growth especially concerning, and the trailing twelve month net loss of US$75.1 million supports their concern that ongoing product and funding pressures are keeping the company in a loss making position.
  • Critics highlight exposure to a small number of large customers and public programs, and the multi year widening of losses in the data lines up with that risk of volatile demand.
  • The expectation in the data that the company is forecast to remain unprofitable over the next three years reinforces the bearish view that it may take time for any new diagnostic offerings to offset current funding and demand headwinds.

For investors who want to see how these funding and customer concentration concerns translate into a full cautious scenario, it can help to read the detailed bear case built around these same figures 🐻 OraSure Technologies Bear Case

P/S Of 2x Versus Peers Despite Ongoing Losses

• The stock trades on a P/S of 2x against a peer average of 2.1x and a US Medical Equipment industry average of 2.8x, while the latest trailing twelve month EPS is a loss of US$1.04 and net income is a loss of US$75.1 million.
• The consensus narrative suggests that new products and cost work could eventually support better margins. The current P/S discount could look more attractive if that happens, but the combination of a US$3.13 share price, a US$5.00 analyst target and forecasts for continued unprofitability shows that the market is still balancing modest revenue growth against a meaningful loss profile.
  • Supporters of the consensus view point to at home and point of care diagnostics as growth areas, yet the revenue base has moved from US$185.8 million to US$113.0 million on a trailing basis in the data, which keeps focus on execution.
  • At the same time, the lower P/S multiple relative to peers indicates that some of this risk is already reflected in the valuation, which is why many investors are watching for any sign of margin improvement before re rating the stock.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for OraSure Technologies on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

See What Else Is Out There

OraSure Technologies is working with modest 5.5% revenue growth, multi year loss expansion and forecasts for continued unprofitability, which keeps earnings risk elevated.

If you want ideas where earnings and valuation risk look more balanced, check out the 72 resilient stocks with low risk scores to quickly spot companies with more resilient profiles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.